Esperite (ESP), The Cell Factory presents pre-clinical results on the new products of the 2nd generation EV’s drugs for treatment of inflammatory diseases

March 29, 2018 Group News
evs-msc

Esperite with its biotech company The Cell Factory has acquired from OPBG the full rights to the IP and the international patent family covering the invention and the therapeutic use of the EV’s products. In collaboration with Women’s and Children’s Health Department of the University of Padua, Italy they are presenting the new generation EV’s biologic drugs bio-activated with Annexin V targeting multiple inflammatory diseases i.e.: Crohn’s disease, drug resistance epilepsy, stroke. The experimental results will be presented during GISM congress in Assisi, Italy in April and ISEV meeting in Barcelona, Spain in May 2018.

Amsterdam, the Netherlands – 29 March 2018

read more

ESPERITE (ESP): transfers its laboratory activity to Geneva and consequently sells its Belgium loss making subsidiary and avoids EUR 4 millions of future cash out for charges and financial costs

January 10, 2018 Group News
DL13216

As Esperite N.V. (Euronext: ESP, “Esperite” or “the Group”) is completing its strategy to concentrate its laboratory activities in its state of the art and fully certified facilities in Geneva, its Belgium subsidiary company CryoSave Labs (“CSL” or the”Company”) is left with no commercial activity and its facility in Neil has become redundant.

Amsterdam, The Netherlands – 10 January 2018

read more

Page 1 of 4012345...102030...Last »